Skip to main content
SpringerLink
Log in

Platinum Resistant Ovarian Cancer

  • Chapter
  • First Online:
Case-Based Gynecological Oncology

  • 195 Accesses

Abstract

Platinum resistance is seen in 25% of all epithelial ovarian cancer. Response to first line therapy is influenced by tumor histology, BRCA status, health related quality of life and use of maintenance therapy with bevacizumab and PARP inhibitors. Treatment of early recurrence (<6 months of completion of primary chemotherapy) usually consists of single agent non platinum drugs like liposomal doxorubicin, paclitaxel, etoposide and the overall response rate is 20–25%. Addition of bevacizumab in select population may give a survival benefit of 4–6 months. Overall survival ranges from 12–24 months. Newer drugs like immune checkpoint inhibitors (anti PD-1 inhibitor pembrolizumab, avelumab), Anti VEGF tyrosine kinase inhibitors (pazopanib, cediranib) and epigenetic therapies are being evaluated in drug trials.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Rustin GJ, van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC, Kristensen G, Mediola C, Coens C, Qian W, Parmar MK, Swart AM. MRC OV05; EORTC 55955 investigators. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet. 2010;376(9747):1155–63.

    Article  PubMed  Google Scholar 

  2. Chuang YT, Chang CL. Extending platinum-free interval in partially platinum-sensitive recurrent ovarian cancer by a non-platinum regimen: its possible clinical significance. Taiwan J Obstet Gynecol. 2012;51(3):336–41.

    Article  PubMed  Google Scholar 

  3. Wilson MK, Pujade-Lauraine E, Aoki D, Mirza MR, Lorusso D, Oza AM, et al. Fifth ovarian cancer consensus conference for the gynecological cancer intergroup; recurrent disease. Ann Oncol. 2017;28:727–32.

    Article  CAS  PubMed  Google Scholar 

  4. Ushijima K. Treatment for recurrent ovarian cancer-at first relapse. J Oncol. 2010;2010:497429.

    Article  PubMed  Google Scholar 

  5. Gupta S, Nag S, Aggarwal S, Rauthan A, Warrier N. Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives - a review. J Ovarian Res. 2019;12(1):103.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Alkema NG, Wisman GB, van der Zee AG, van Vugt MA, de Jong S. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: different models for different questions. Drug Resist Updat. 2016;24:55–69.

    Article  PubMed  Google Scholar 

  7. Pujade-Lauraine E, Banerjee S, Pignata S. Management of platinum-resistant, relapsed epithelial ovarian cancer and new drug perspectives. J Clin Oncol. 2019;37(27):2437–48.

    Article  CAS  PubMed  Google Scholar 

  8. Oncolato FT, Joly F, O’Connell R, Lanceley A, Hilpert F, Buizen L, et al. GCIG Symptom Benefit group. Reducing uncertainty: predictors of stopping chemotherapy early and shortened survival time in platinum resistant/refractory ovarian cancer-the GCIG symptom benefit study. Oncologist. 2017;22(9):1117–24.

    Article  Google Scholar 

  9. Markman M, Hall J, Spitz D, et al. Phase II trial of weekly single agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J Clin Oncol. 2002;20:2365–9.

    Article  CAS  PubMed  Google Scholar 

  10. ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol. 1997;15:2183–93.

    Article  PubMed  Google Scholar 

  11. Oronsky B, Ray CM, Spira AI, Trepel JB, Carter CA, Cottrill HM. A brief review of the management of platinum-resistant–platinum-refractory ovarian cancer. Med Oncol. 2017;34:103.

    Article  PubMed  Google Scholar 

  12. Ganghadaran SGD. Management of platinum resistant—refractory ovarian cancer: a short review. J Cancer Res Treat. 2016;4(2):32–6.

    CAS  Google Scholar 

  13. Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32(13):1302–8.

    Article  CAS  PubMed  Google Scholar 

  14. Kim G, et al. FDA approval summary: olaparib monotherapy inpatients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy. Clin Cancer Res. 2015;21(19):4257–61.

    Article  CAS  PubMed  Google Scholar 

  15. Indini A, Nigro O, Lengyel CG, Ghidini M, Petrillo A, Lopez S, et al. Immune checkpoint inhibitors in platinum resistant ovarian cancers. Cancers (Basel). 2021;13(7):1663.

    Article  CAS  PubMed  Google Scholar 

  16. Marchetti C, Palaia I, De Felice F, Musella A, Donfracesco C, Vertechy L, Romito A, Piacenti I, Musio D, Muzii L, Tombolini V, Benedetti Panici P. Tyrosine-kinases inhibitors in recurrent platinum-resistant ovarian cancer patients. Cancer Treat Rev. 2016;42:41–6.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Birmingham City Hospital, Birmingham, UK

    Kavita Singh

  2. UCMS and GTB Hospital, New Delhi, India

    Bindiya Gupta

Authors
  1. Kavita Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bindiya Gupta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kavita Singh .

Editor information

Editors and Affiliations

  1. Birmingham City Hospital, Birmingham, UK

    Kavita Singh

  2. UCMS and GTB Hospital, New Delhi, India

    Bindiya Gupta

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Singh, K., Gupta, B. (2023). Platinum Resistant Ovarian Cancer. In: Singh, K., Gupta, B. (eds) Case-Based Gynecological Oncology. Springer, Cham. https://doi.org/10.1007/978-3-031-36179-1_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-36179-1_6

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-36178-4

  • Online ISBN: 978-3-031-36179-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation